Thymoma

This trial studies sacituzumab govitecan-hziy in adults with advanced thymoma and thymic carcinoma who have progressed after at least one prior treatment. The main goal is to find the overall response rate in these patients, which helps understand how the cancer responds to this therapy. The study is a Phase II trial led by Georgetown University focusing on this rare and advanced cancer type. Participants receive sacituzumab govitecan-hziy at a fixed dose of 10 mgkg intravenously once weekly on Days 1 and 8 within 21-day cycles. Treatment continues until the cancer progresses or side effects become unacceptable. This approach allows ongoing monitoring of effects and tolerability over repeated cycles. During the study, participants will have regular blood tests, scans, and physical exams to track health and cancer status. Researchers will collect blood and tumor biopsies for research. They will measure outcomes like overall response rate at one year, duration of response, progression-free survival, and overall survival, with safety closely monitored throughout the treatment period.

Researchers are evaluating the combination of Adebrelimab with carboplatin or cisplatin plus etoposide chemotherapy and concurrent radiotherapy as a first treatment for patients with extensive-stage oligometastatic small cell lung cancer. This Phase II open-label study aims to assess the safety and effectiveness of this regimen in this patient group. The trial is led by Nanfang Hospital, Southern Medical University and focuses on patients with limited metastatic lesions and organs affected. Participants will first receive Adebrelimab intravenously along with carboplatin or cisplatin and etoposide for two cycles during the induction phase. Next, participants undergo concurrent chemoradiotherapy, including thoracic radiation and stereotactic body radiation therapy SBRT to metastases, combined with one to two cycles of chemotherapy. Following this, they will receive one to two additional cycles of Adebrelimab combined with chemotherapy, and then continue on Adebrelimab alone as maintenance therapy until disease progression, unacceptable side effects, or withdrawal from the study. During the study, participants will be closely monitored through clinical assessments, imaging, and laboratory tests to track progression-free survival and other measures such as overall survival and response rates, with follow-up lasting up to approximately 30 months. Safety will be monitored by recording adverse events throughout the treatment and maintenance phases. The total participation time includes induction, concurrent chemoradiotherapy, maintenance, and follow-up periods to fully evaluate treatment outcomes and tolerability.

Researchers are studying whether a virtual mind-body program called Integrative Medicine at Home IMHome can improve how people with various types of cancer feel and experience treatment. This research focuses on patients undergoing systemic cancer treatments such as chemotherapy, immunotherapy, radiotherapy, targeted therapies, or surgery. The goal is to assess patient-reported outcomes, values, and experiences during these treatments. Participants are randomly assigned to one of two groups. One group takes part in a 12-week virtual mind-body and fitness program via Zoom, choosing from weekly classes like yoga, dance therapy, tai chi, meditation, or music therapy led by specialized therapists. Each class lasts 30 to 45 minutes. The other group receives enhanced usual care, including a handout and access to on-demand meditation and relaxation recordings online. During the study, participants will be monitored for 12 weeks. Researchers will evaluate fatigue severity, symptom intensity, insomnia, psychological distress, pain, treatment expectations, satisfaction with the intervention, and healthcare usage such as treatment disruptions and unplanned medical visits. Attendance to the IMHome sessions will also be tracked. This comprehensive approach aims to understand how the program may affect patients well-being while undergoing cancer treatment.

Researchers are evaluating hemithoracic intensity-modulated pleural radiation therapy IMPRINT to determine if it is a safe treatment option with minimal side effects for people with thymic malignancies that have spread to the lining of the lungs and chest. The study also aims to assess whether this radiation therapy is effective against cancer in these patients. This is a Phase II clinical trial sponsored by Memorial Sloan Kettering Cancer Center. Participants will receive radiation therapy over about 6 weeks, with a total dose of 50.4 Gy given in 28 sessions. There is an option for a higher dose to areas of visible remaining cancer while protecting normal tissues. This treatment targets the affected hemithoracic pleura, the lining of one side of the chest. During the study, participants will be monitored for side effects such as radiation pneumonitis over two years. Researchers will also measure progression-free survival at 12 months to see how well the cancer is controlled. Participants will have regular assessments including lung function tests and kidney function evaluations to ensure safety, with study participation lasting for at least two years of follow-up.

Researchers are evaluating the safety and effectiveness of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma, which are rare types of thoracic tumors. This phase II, open-label, single-arm study aims to address the urgent need for effective treatments in patients who have not benefited from first-line chemotherapy. Previous phase I studies showed promising results for KC1036, supporting further investigation. Participants will take 60 mg of KC1036 orally once daily in 21-day treatment cycles. Safety assessments will occur every 21 days, and tumor responses will be evaluated every two cycles. Treatment continues until the disease progresses, unacceptable side effects occur, or the patient chooses to stop. This multicenter study is sponsored by Beijing Konruns Pharmaceutical Co., Ltd. During the study, participants will undergo regular evaluations including tumor imaging to measure response and safety monitoring over approximately two years. Researchers will assess outcomes such as objective response rate, progression-free survival, disease control rate, duration of response, and adverse events. The study includes adults aged 18 to 75 with confirmed thymic tumors and measurable lesions, requiring ongoing monitoring throughout participation.

Researchers are evaluating the safety and effectiveness of different drug treatments in people with myasthenia gravis, a condition that affects muscle strength. This platform study uses a single master protocol to test multiple treatment regimens in separate groups called intervention-specific appendixes ISAs. The goal is to find the best treatments that reduce side effects and improve quality of life for patients with this disease. The study includes various treatment groups, such as those receiving intravenous infusions of efgartigimod, empasiprubart, or placebo, and subcutaneous administration of efgartigimod PH20 via pre-filled syringe. Each ISA has its own screening, treatment, and safety follow-up periods, which vary in length and design. Two ISAs are included one evaluating empasiprubart as add-on therapy to efgartigimod in people with partial responses, and another assessing empasiprubart monotherapy. Participants are involved in screening and treatment phases, with assessments of safety, tolerability, and effectiveness lasting up to about seven years depending on the ISA. Researchers will monitor clinical symptoms, side effects, and quality of life during and after treatment. The study aims to gather detailed information on how well these drug regimens work and their impact on patients living with myasthenia gravis.

This research aims to evaluate the safety and therapeutic importance of empasiprubart as an add-on treatment to efgartigimod in adults with AChR-Ab seropositive generalized myasthenia gravis who have a partial clinical response to efgartigimod. It is part of the ADAPT Forward platform study, which looks at the safety and effectiveness of different drugs to find the best ways to reduce side effects and improve quality of life for people with myasthenia gravis. Participants first complete screening and then enter a run-in period part A receiving efgartigimod intravenously. Those eligible move on to the add-on period part B, receiving both efgartigimod and empasiprubart intravenously. Participants not eligible for part B continue to a safety follow-up period part C where they receive efgartigimod only. The total study duration is approximately 54 weeks per participant. Throughout the study, participants undergo assessments including monitoring for adverse events, measuring changes in MG-ADL and QMG scores, and evaluating clinical responses. Researchers track safety and efficacy up to 21 weeks during parts A and B. Participants have scheduled visits for treatment and safety evaluations, with ongoing observation through the safety follow-up period to monitor treatment effects and side effects.

Researchers are studying whether adding radiotherapy after complete surgical removal improves survival in patients with stage II or III thymoma. This study aims to clarify the benefit of adjuvant radiotherapy since previous research shows better outcomes with complete resection but the role of additional radiotherapy remains unclear. The trial is sponsored by Fudan University and focuses on patients with this specific type and stage of thymoma. Participants are randomly assigned to one of two groups one group receives adjuvant radiotherapy delivering a total of 50Gy divided into 25 sessions after their complete tumor removal, while the other group undergoes complete resection alone without further treatment. This open-label, multi-center trial compares these approaches to assess their impact on survival. Throughout the study, participants will be monitored for disease-free survival over five years as the main outcome. Secondary measures include overall survival and tracking any treatment-related side effects using standard criteria. Patients will undergo regular follow-ups and evaluations to assess their health status and treatment effects during this period, which lasts up to five years after enrollment.

This research focuses on children and adolescents with very rare tumors that occur at an annual rate of less than two per million children. These tumors include a wide variety of cancers, some rarely seen at any age and others more typical in adults but rare in pediatric patients. The study aims to gather detailed data to better understand these tumors and how their clinical and biological traits influence treatment outcomes, addressing the current lack of unified diagnostic criteria and information. The study is an international, prospective observational study supported by Padua University Hospital AOUP and the European Reference Network for Paediatric Oncology. It collects epidemiological, clinical, biological, radiological, and treatment data without proposing specific treatments. Collaboration across various European centers allows for comprehensive data collection to improve future diagnosis and treatment recommendations. Participants will be children and adolescents between birth and 18 years old diagnosed or treated for very rare tumors at participating centers. Researchers will collect and analyze data on epidemiology, adherence to international recommendations, and survival outcomes over about one year. The study involves no intervention but monitors participants clinical progress through data gathering to enhance knowledge and care for rare pediatric cancers.

This research evaluates a new treatment using genetically modified T cells, called TNhYP218 CAR T cells, for adults with mesothelin-expressing solid tumors, including mesothelioma. Mesothelioma is an aggressive cancer affecting the linings of organs, and mesothelin is a protein found in high amounts in many tumors. The study aims to test the safety, dosing, and preliminary effectiveness of this immune-based therapy in people whose tumors have returned or spread after standard treatments. Participants will first undergo screening including a biopsy to check mesothelin levels in their tumors. They will have their own T cells collected through a blood process called leukapheresis. These T cells are then modified in a laboratory to target mesothelin. Before receiving the treatment, participants will be given chemotherapy drugs to prepare their bodies. The modified T cells are infused intravenously, and participants will stay in the hospital for about a week after infusion. The study includes a dose-escalation phase and a dose-expansion phase to find the recommended dose and assess response. During the study, participants will have regular follow-up visits for up to 15 years to monitor safety and treatment effects. These visits may include imaging scans, blood tests, heart function tests, and additional biopsies. Researchers will closely watch for side effects, tumor response, progression-free survival, and overall survival. The total participation time includes treatment, hospital stay, and long-term monitoring to evaluate the therapys impact over many years.